Analyses of Direct and Indirect Impacts of a Positive List System on Pharmaceutical R&D Investments

Euna Han, Tae Hyun Kim, Myung Jin Jeung, Eui Kyung Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The South Korean government recently enacted a Positive List System (PLS) as a major change of the national formulary listing system and reimbursed prices for pharmaceutical products. Regardless of the primary goal of the PLS, its implementation might have spillover effects by influencing the pharmaceutical industry's research and development (R&D), potentially leading to a variety of responses by firms in relation to their R&D activities. Objective: We investigated the spillover effect of the PLS on R&D investments of the pharmaceutical industry in Korea through both direct and indirect channels, examining the influence of the PLS on sales profit and cash flow. Methods: Data from 9 years (5 before and 4 after PLS implementation) were drawn from the financial statements of firms whose stocks were exchanged in 2 official stock markets in Korea (526 firms) and additional pharmaceutical firms whose financial performance was officially audited by external reviewers (263 firms). Longitudinal analyses were conducted, using the panel nature of the data to control for permanent unobserved firm heterogeneity. Results: Our results showed that the PLS was directly associated with R&D investments. In contrast, its indirect impacts stemming from the influence on sales profit and cash flow were minimal and statistically nonsignificant. The gross impact of the PLS on R&D investments increased moving further from the enactment year; R&D investments were reduced by 18.3% to 25.8% in 2009-2010 (compared with before PLS implementation) in the firm fixed-effects model. We also found that such negative direct and gross impacts of the PLS on R&D investments were significant only in firms without newly developed chemical entities. Conclusion: Considering the gross negative impact of the PLS on R&D investments of pharmaceutical firms and the heterogeneous response of these firms by the R&D activities, governmental efforts of cost-containment may need to consider the spillover impact of the PLS on pharmaceutical innovation.

Original languageEnglish
Pages (from-to)941-949
Number of pages9
JournalClinical Therapeutics
Volume35
Issue number7
DOIs
Publication statusPublished - 2013 Jul 1

Fingerprint

Pharmaceutical Preparations
Drug Industry
Korea
Pharmacopoeias
Cost Control
Research
Pharmaceutical Research
Financial Statements

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Han, Euna ; Kim, Tae Hyun ; Jeung, Myung Jin ; Lee, Eui Kyung. / Analyses of Direct and Indirect Impacts of a Positive List System on Pharmaceutical R&D Investments. In: Clinical Therapeutics. 2013 ; Vol. 35, No. 7. pp. 941-949.
@article{2cc6bbeb99fb4d6481a4cc69cd420b3f,
title = "Analyses of Direct and Indirect Impacts of a Positive List System on Pharmaceutical R&D Investments",
abstract = "Background: The South Korean government recently enacted a Positive List System (PLS) as a major change of the national formulary listing system and reimbursed prices for pharmaceutical products. Regardless of the primary goal of the PLS, its implementation might have spillover effects by influencing the pharmaceutical industry's research and development (R&D), potentially leading to a variety of responses by firms in relation to their R&D activities. Objective: We investigated the spillover effect of the PLS on R&D investments of the pharmaceutical industry in Korea through both direct and indirect channels, examining the influence of the PLS on sales profit and cash flow. Methods: Data from 9 years (5 before and 4 after PLS implementation) were drawn from the financial statements of firms whose stocks were exchanged in 2 official stock markets in Korea (526 firms) and additional pharmaceutical firms whose financial performance was officially audited by external reviewers (263 firms). Longitudinal analyses were conducted, using the panel nature of the data to control for permanent unobserved firm heterogeneity. Results: Our results showed that the PLS was directly associated with R&D investments. In contrast, its indirect impacts stemming from the influence on sales profit and cash flow were minimal and statistically nonsignificant. The gross impact of the PLS on R&D investments increased moving further from the enactment year; R&D investments were reduced by 18.3{\%} to 25.8{\%} in 2009-2010 (compared with before PLS implementation) in the firm fixed-effects model. We also found that such negative direct and gross impacts of the PLS on R&D investments were significant only in firms without newly developed chemical entities. Conclusion: Considering the gross negative impact of the PLS on R&D investments of pharmaceutical firms and the heterogeneous response of these firms by the R&D activities, governmental efforts of cost-containment may need to consider the spillover impact of the PLS on pharmaceutical innovation.",
author = "Euna Han and Kim, {Tae Hyun} and Jeung, {Myung Jin} and Lee, {Eui Kyung}",
year = "2013",
month = "7",
day = "1",
doi = "10.1016/j.clinthera.2013.05.002",
language = "English",
volume = "35",
pages = "941--949",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "7",

}

Analyses of Direct and Indirect Impacts of a Positive List System on Pharmaceutical R&D Investments. / Han, Euna; Kim, Tae Hyun; Jeung, Myung Jin; Lee, Eui Kyung.

In: Clinical Therapeutics, Vol. 35, No. 7, 01.07.2013, p. 941-949.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Analyses of Direct and Indirect Impacts of a Positive List System on Pharmaceutical R&D Investments

AU - Han, Euna

AU - Kim, Tae Hyun

AU - Jeung, Myung Jin

AU - Lee, Eui Kyung

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Background: The South Korean government recently enacted a Positive List System (PLS) as a major change of the national formulary listing system and reimbursed prices for pharmaceutical products. Regardless of the primary goal of the PLS, its implementation might have spillover effects by influencing the pharmaceutical industry's research and development (R&D), potentially leading to a variety of responses by firms in relation to their R&D activities. Objective: We investigated the spillover effect of the PLS on R&D investments of the pharmaceutical industry in Korea through both direct and indirect channels, examining the influence of the PLS on sales profit and cash flow. Methods: Data from 9 years (5 before and 4 after PLS implementation) were drawn from the financial statements of firms whose stocks were exchanged in 2 official stock markets in Korea (526 firms) and additional pharmaceutical firms whose financial performance was officially audited by external reviewers (263 firms). Longitudinal analyses were conducted, using the panel nature of the data to control for permanent unobserved firm heterogeneity. Results: Our results showed that the PLS was directly associated with R&D investments. In contrast, its indirect impacts stemming from the influence on sales profit and cash flow were minimal and statistically nonsignificant. The gross impact of the PLS on R&D investments increased moving further from the enactment year; R&D investments were reduced by 18.3% to 25.8% in 2009-2010 (compared with before PLS implementation) in the firm fixed-effects model. We also found that such negative direct and gross impacts of the PLS on R&D investments were significant only in firms without newly developed chemical entities. Conclusion: Considering the gross negative impact of the PLS on R&D investments of pharmaceutical firms and the heterogeneous response of these firms by the R&D activities, governmental efforts of cost-containment may need to consider the spillover impact of the PLS on pharmaceutical innovation.

AB - Background: The South Korean government recently enacted a Positive List System (PLS) as a major change of the national formulary listing system and reimbursed prices for pharmaceutical products. Regardless of the primary goal of the PLS, its implementation might have spillover effects by influencing the pharmaceutical industry's research and development (R&D), potentially leading to a variety of responses by firms in relation to their R&D activities. Objective: We investigated the spillover effect of the PLS on R&D investments of the pharmaceutical industry in Korea through both direct and indirect channels, examining the influence of the PLS on sales profit and cash flow. Methods: Data from 9 years (5 before and 4 after PLS implementation) were drawn from the financial statements of firms whose stocks were exchanged in 2 official stock markets in Korea (526 firms) and additional pharmaceutical firms whose financial performance was officially audited by external reviewers (263 firms). Longitudinal analyses were conducted, using the panel nature of the data to control for permanent unobserved firm heterogeneity. Results: Our results showed that the PLS was directly associated with R&D investments. In contrast, its indirect impacts stemming from the influence on sales profit and cash flow were minimal and statistically nonsignificant. The gross impact of the PLS on R&D investments increased moving further from the enactment year; R&D investments were reduced by 18.3% to 25.8% in 2009-2010 (compared with before PLS implementation) in the firm fixed-effects model. We also found that such negative direct and gross impacts of the PLS on R&D investments were significant only in firms without newly developed chemical entities. Conclusion: Considering the gross negative impact of the PLS on R&D investments of pharmaceutical firms and the heterogeneous response of these firms by the R&D activities, governmental efforts of cost-containment may need to consider the spillover impact of the PLS on pharmaceutical innovation.

UR - http://www.scopus.com/inward/record.url?scp=84880509581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880509581&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2013.05.002

DO - 10.1016/j.clinthera.2013.05.002

M3 - Article

VL - 35

SP - 941

EP - 949

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 7

ER -